Biopreservation Market

Executive Summary

Biopreservation Market was valued at US $4.89 billion in 2021 and is projected to grow at 8.67% CAGR over the forecast period to reach US $8.05 billion by 2027. Biopreservation Market represented US $0.75 billion opportunity over 2019-2021 and estimated to create US $3.16 billion opportunity in 2027 over 2021.

Biopreservation from Consainsights analyses the Biopreservation Market in the Life Sciences industry over the forecast period to 2027.

Biopreservation research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Biopreservation segmentation includes Type, Biospecimen, Application, End User, Region and Geography.

Based on the Type, the Biopreservation analysis covers Biopreservation Media, Biopreservation Equipment.

In Type segment, Biopreservation Media segment has highest cagr growth of 7.67%.

Based on the Biospecimen, the Biopreservation analysis covers Human Tissue Samples, Organs, Stem Cells, Other Biospecimens.

In Biospecimen segment, Human Tissue Samples segment has highest cagr growth of 7.67%.

Based on the Application, the Biopreservation analysis covers Therapeutic Applications, Research Applications, Clinical Trials, Other Applications.

In Application segment, Therapeutic Applications segment has highest cagr growth of 7.67%.

Based on the End User, the Biopreservation analysis covers Biobanks, Gene Banks, Hospitals, Other End Users.

In End User segment, Biobanks segment has highest cagr growth of 7.67%.

Based on the Region, the Biopreservation analysis covers North America, Europe, Asia Pacific, Rest of the World (Row).

In Region segment, North America segment has highest cagr growth of 7.67%.

Based on the region, the Biopreservation analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Thermo Fisher Scientific, Inc., Merck Kgaa, Avantor, Inc., Thermogenesis Holdings, Inc., Bio-Techne Corporation, Biolife Solutions, Inc., Exact Sciences Corporation, Worthington Industries, Inc., Chart Industries, Inc., So-Low Environmental Equipment Co., Inc., Princeton Cryotech, Inc., Biocision, Llc., Shanghai Genext Medical Technology Co., Ltd., Phc Holdings Corporation, Helmer Scientific, Inc., Arctiko, Nippon Genetics Europe, Stemcell Technologies, Inc., Ams Biotechnology (Amsbio), Ops Diagnostics and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Biopreservation Equipment segment has the highest revenue of US $2.74 billion and is expected to grow at CAGR of 7.67% by 2027 Biopreservation Media segment has highest cagr growth of 7.67%.

Biopreservation Media

Biopreservation Media segment was valued at US $1.82 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $3.55 billion by 2027. Biopreservation Media segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.39 billion opportunity in 2027 over 2021.

Biopreservation Equipment

Biopreservation Equipment segment was valued at US $2.32 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $4.51 billion by 2027. Biopreservation Equipment segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.77 billion opportunity in 2027 over 2021.

Biospecimen

Introduction

In 2021, Human Tissue Samples segment has the highest revenue of US $1.97 billion and is expected to grow at CAGR of 7.67% by 2027 Human Tissue Samples segment has highest cagr growth of 7.67%.

Human Tissue Samples

Human Tissue Samples segment was valued at US $1.67 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $3.25 billion by 2027. Human Tissue Samples segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.28 billion opportunity in 2027 over 2021.

Organs

Organs segment was valued at US $1.06 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $2.06 billion by 2027. Organs segment represented US $0.19 billion opportunity over 2019-2021 and estimated to create US $0.81 billion opportunity in 2027 over 2021.

Stem Cells

Stem Cells segment was valued at US $0.92 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.78 billion by 2027. Stem Cells segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.70 billion opportunity in 2027 over 2021.

Other Biospecimens

Other Biospecimens segment was valued at US $0.50 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $0.96 billion by 2027. Other Biospecimens segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Therapeutic Applications segment has the highest revenue of US $2.60 billion and is expected to grow at CAGR of 7.67% by 2027 Therapeutic Applications segment has highest cagr growth of 7.67%.

Therapeutic Applications

Therapeutic Applications segment was valued at US $2.20 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $4.28 billion by 2027. Therapeutic Applications segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.68 billion opportunity in 2027 over 2021.

Research Applications

Research Applications segment was valued at US $1.29 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $2.51 billion by 2027. Research Applications segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.98 billion opportunity in 2027 over 2021.

Clinical Trials

Clinical Trials segment was valued at US $0.41 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $0.80 billion by 2027. Clinical Trials segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.31 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.24 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $0.47 billion by 2027. Other Applications segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Biobanks segment has the highest revenue of US $2.24 billion and is expected to grow at CAGR of 7.67% by 2027 Biobanks segment has highest cagr growth of 7.67%.

Biobanks

Biobanks segment was valued at US $1.90 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $3.69 billion by 2027. Biobanks segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.45 billion opportunity in 2027 over 2021.

Gene Banks

Gene Banks segment was valued at US $1.00 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.94 billion by 2027. Gene Banks segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.76 billion opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $0.62 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.21 billion by 2027. Hospitals segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.47 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $0.63 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.22 billion by 2027. Other End Users segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.48 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $2.46 billion and is expected to grow at CAGR of 7.67% by 2027 North America segment has highest cagr growth of 7.67%.

North America

North America segment was valued at US $2.08 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $4.05 billion by 2027. North America segment represented US $0.38 billion opportunity over 2019-2021 and estimated to create US $1.59 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.84 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.64 billion by 2027. Europe segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.64 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.84 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $1.63 billion by 2027. Asia Pacific segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.64 billion opportunity in 2027 over 2021.

Rest of the World (Row)

Rest of the World (Row) segment was valued at US $0.38 billion in 2019 and is projected to grow at 7.67% CAGR over the forecast period to reach US $0.74 billion by 2027. Rest of the World (Row) segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.29 billion opportunity in 2027 over 2021.